MARATTO

article · International Journal of Molecular Sciences

Long Intergenic Non-Coding RNA 00511 (LINC00511) Genetic Variations and Haplotypes in Breast Cancer: A Case-Controlled Study and Bioinformatics Analysis

20253 citationsOpen accessBritish University in Egypt

Abstract

Long intergenic non-coding RNA 00511 (LINC00511) has been involved in the development of several types of cancer including breast cancer (BC). Several single nucleotide polymorphisms (SNPs) can be found in the genomic regions of long non-coding RNAs (lncRNAs) and are associated with the tumorigenesis of many cancers. The objective of the current study is to assess whether LINC00511 SNPs (rs11657109, rs9906859, rs17780195, rs1558535, and rs4432291) could be related with BC incidence in the Egyptian population. Five SNPs of LINC00511 were analyzed in a case–control study of 267 BC cases and 150 controls. Logistic regression analysis was used to test the association between LINC00511 SNPs and BC incidence. We found that the TT genotype of rs11657109 significantly increased BC incidence (OR: 2.177, 95%CI: 1.260–3.763) and this SNP was associated with high incidence of luminal A BC specifically using different genetic models. Haplotype (A09 A91 A35 G95 T59) was strongly associated with an increased BC incidence as it was totally absent in controls. These findings suggest that LINC00511 SNP rs11657109 is associated with BC susceptibility in the Egyptian population.

Research topics

  • Cancer-related molecular mechanisms research
  • Molecular Biology Techniques and Applications
  • Mycobacterium research and diagnosis

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3390/ijms26199328

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.